SCHEMBL30348778

SCHEMBL30348778

CN1CCN(c2ccc(Nc3ncc4c(-c5ccc6ncnn6c5)c[nH]c4n3)cn2)CC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 2/20 0.51
CLK2 P49760 1/20 0.51
CLK3 P49761 1/20 0.51
TDO2 P48775 1/20 0.44
MAP4K4 O95819 1/20 0.43
WEE1 P30291 1/20 0.42
IL2 P60568 1/20 0.42
MAP4K1 Q92918 1/20 0.42
JAK2 O60674 3/20 0.40
JAK3 P52333 3/20 0.40
PTK2 Q05397 1/20 0.40
JAK1 P23458 2/20 0.39
CYP3A4 P08684 1/20 0.39
CTSC P53634 1/20 0.39
BTK Q06187 1/20 0.39
TTK P33981 1/20 0.39
TGFBR1 P36897 1/20 0.38
MAPK14 Q16539 1/20 0.38
IGF1R P08069 1/20 0.38
CDK2 P24941 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25157507 1.00 DYRK1A (0.51) DYRK1ACLK2CLK3TDO2MAP4K4
SCHEMBL30347751 0.88 DYRK1A (0.67) DYRK1ACLK2CLK3TDO2MAP4K4
SCHEMBL25157505 0.88 DYRK1A (0.67) DYRK1ACLK2CLK3TDO2MAP4K4
SCHEMBL30347825 0.87 DYRK1A (0.43) DYRK1ACLK2CLK3TDO2MAP4K4
SCHEMBL25518653 0.87 DYRK1A (0.43) DYRK1ACLK2CLK3TDO2MAP4K4
SCHEMBL30348901 0.85 DYRK1A (0.49) DYRK1ACLK2CLK3TDO2MAP4K4
SCHEMBL25206720 0.85 DYRK1A (0.49) DYRK1ACLK2CLK3TDO2MAP4K4
SCHEMBL25214166 0.85 CDK2 (0.53) DYRK1ACLK2CLK3WEE1JAK2
SCHEMBL30348240 0.85 CDK2 (0.53) DYRK1ACLK2CLK3WEE1JAK2
SCHEMBL25194564 0.85 CLK2 (0.53) DYRK1ACLK2CLK3TDO2WEE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4415818-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AS DYRK1A INHIBITORS BioSplice Therapeutics, Inc. (US) 2024-08-21 EP claimed
US-20230167133-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF VICKERS VENTURE FUND VI PTE. LTD. (SG) 2023-06-01 US claimed
WO-2023064361-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AS DYRK1A INHIBITORS BIOSPLICE THERAPEUTICS, INC. (US) 2023-04-20 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230167133-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF DYRK1A, DYRK1B, DYRK2 DYRK1A 1/4885CLK2 466/4885CLK3 1147/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.